183 related articles for article (PubMed ID: 19199865)
41. Src homology 2 domain-containing protein-tyrosine phosphatases, SHP-1 and SHP-2, are required for platelet endothelial cell adhesion molecule-1/CD31-mediated inhibitory signaling.
Henshall TL; Jones KL; Wilkinson R; Jackson DE
J Immunol; 2001 Mar; 166(5):3098-106. PubMed ID: 11207261
[TBL] [Abstract][Full Text] [Related]
42. Proteinaceous Regulators and Inhibitors of Protein Tyrosine Phosphatases.
Hendriks W; Bourgonje A; Leenders W; Pulido R
Molecules; 2018 Feb; 23(2):. PubMed ID: 29439552
[TBL] [Abstract][Full Text] [Related]
43. Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1.
Pei D; Wang J; Walsh CT
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1141-5. PubMed ID: 8577729
[TBL] [Abstract][Full Text] [Related]
44. Tyrosine phosphatases SHP-1 and SHP-2 are associated with distinct tyrosine-phosphorylated proteins.
Xu F; Xu MJ; Zhao R; Guerrah A; Zeng F; Zhao ZJ
Exp Cell Res; 2002 Jan; 272(1):75-83. PubMed ID: 11740867
[TBL] [Abstract][Full Text] [Related]
45. Kinetic comparison of the catalytic domains of SHP-1 and SHP-2.
Niu T; Liang X; Yang J; Zhao Z; Zhou GW
J Cell Biochem; 1999 Jan; 72(1):145-50. PubMed ID: 10025675
[TBL] [Abstract][Full Text] [Related]
46. Small molecule inhibitors of dual specificity protein phosphatases.
Pestell KE; Ducruet AP; Wipf P; Lazo JS
Oncogene; 2000 Dec; 19(56):6607-12. PubMed ID: 11426646
[TBL] [Abstract][Full Text] [Related]
47. Interaction of SH2-containing protein tyrosine phosphatase 2 with the insulin receptor and the insulin-like growth factor-I receptor: studies of the domains involved using the yeast two-hybrid system.
Rocchi S; Tartare-Deckert S; Sawka-Verhelle D; Gamha A; van Obberghen E
Endocrinology; 1996 Nov; 137(11):4944-52. PubMed ID: 8895367
[TBL] [Abstract][Full Text] [Related]
48. Dual-specificity phosphatases as targets for antineoplastic agents.
Lyon MA; Ducruet AP; Wipf P; Lazo JS
Nat Rev Drug Discov; 2002 Dec; 1(12):961-76. PubMed ID: 12461518
[TBL] [Abstract][Full Text] [Related]
49. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.
Saxton TM; Henkemeyer M; Gasca S; Shen R; Rossi DJ; Shalaby F; Feng GS; Pawson T
EMBO J; 1997 May; 16(9):2352-64. PubMed ID: 9171349
[TBL] [Abstract][Full Text] [Related]
50. The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients.
Akagi S; Ichikawa H; Okada T; Sarai A; Sugimoto T; Morimoto H; Kihara T; Yano A; Nakao K; Nagake Y; Wada J; Makino H
J Am Soc Nephrol; 2004 Dec; 15(12):3215-24. PubMed ID: 15579525
[TBL] [Abstract][Full Text] [Related]
51. Crystal structure of the tyrosine phosphatase SHP-2.
Hof P; Pluskey S; Dhe-Paganon S; Eck MJ; Shoelson SE
Cell; 1998 Feb; 92(4):441-50. PubMed ID: 9491886
[TBL] [Abstract][Full Text] [Related]
52. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
53. Discovery and Evaluation of PRL Trimer Disruptors for Novel Anticancer Agents.
Bai Y; Yu ZH; Zhang ZY
Methods Mol Biol; 2016; 1447():121-38. PubMed ID: 27514804
[TBL] [Abstract][Full Text] [Related]
54. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia.
Kim HY; Park EJ; Joe EH; Jou I
J Immunol; 2003 Dec; 171(11):6072-9. PubMed ID: 14634121
[TBL] [Abstract][Full Text] [Related]
55. Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated Shc and mitogen-activated protein kinase activation in vascular smooth muscle cells.
Ling Y; Maile LA; Lieskovska J; Badley-Clarke J; Clemmons DR
Mol Biol Cell; 2005 Jul; 16(7):3353-64. PubMed ID: 15888547
[TBL] [Abstract][Full Text] [Related]
56. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
Min G; Lee SK; Kim HN; Han YM; Lee RH; Jeong DG; Han DC; Kwon BM
Bioorg Med Chem Lett; 2013 Jul; 23(13):3769-74. PubMed ID: 23726031
[TBL] [Abstract][Full Text] [Related]
57. Targeting Src homology 2 domain-containing tyrosine phosphatase (SHP-1) into lipid rafts inhibits CD3-induced T cell activation.
Su MW; Yu CL; Burakoff SJ; Jin YJ
J Immunol; 2001 Mar; 166(6):3975-82. PubMed ID: 11238643
[TBL] [Abstract][Full Text] [Related]
58. Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition.
Schneider H; Rudd CE
Biochem Biophys Res Commun; 2000 Mar; 269(1):279-83. PubMed ID: 10694513
[TBL] [Abstract][Full Text] [Related]
59. Determination of the binding specificity of the SH2 domains of protein tyrosine phosphatase SHP-1 through the screening of a combinatorial phosphotyrosyl peptide library.
Beebe KD; Wang P; Arabaci G; Pei D
Biochemistry; 2000 Oct; 39(43):13251-60. PubMed ID: 11052678
[TBL] [Abstract][Full Text] [Related]
60. Immunoreceptor tyrosine-based inhibitory motif of the IL-4 receptor associates with SH2-containing phosphatases and regulates IL-4-induced proliferation.
Kashiwada M; Giallourakis CC; Pan PY; Rothman PB
J Immunol; 2001 Dec; 167(11):6382-7. PubMed ID: 11714803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
